See more : Aurora Innovation, Inc. (AUROW) Income Statement Analysis – Financial Results
Complete financial analysis of Vivos Inc. (RDGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivos Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Atec, Inc. (ATCN) Income Statement Analysis – Financial Results
- Transportadora de Gas del Sur S.A. (TGS) Income Statement Analysis – Financial Results
- Frontera Investment, Inc. (FRNV) Income Statement Analysis – Financial Results
- Obara Group Incorporated (6877.T) Income Statement Analysis – Financial Results
- AZEARTH Corporation (3161.T) Income Statement Analysis – Financial Results
Vivos Inc. (RDGL)
About Vivos Inc.
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.50K | 36.50K | 14.89K | 7.00K | 9.50K | 0.00 | 4.05K | 8.11K | 24.11K | 24.11K | 140.60K | 247.97K | 393.60K | 360.61K | 320.36K | 268.24K | 130.06K |
| Cost of Revenue | 25.54K | 28.78K | 12.00K | 5.61K | 6.03K | 0.00 | 1.47K | 2.95K | 474.00 | 1.10K | 105.33K | 72.82K | 64.04K | 70.13K | 125.69K | 155.46K | 55.84K |
| Gross Profit | -6.04K | 7.72K | 2.89K | 1.39K | 3.47K | 0.00 | 2.58K | 5.16K | 23.63K | 23.00K | 35.27K | 175.15K | 329.56K | 290.48K | 194.68K | 112.79K | 74.21K |
| Gross Profit Ratio | -30.95% | 21.15% | 19.39% | 19.89% | 36.55% | 0.00% | 63.67% | 63.65% | 98.03% | 95.42% | 25.09% | 70.63% | 83.73% | 80.55% | 60.77% | 42.05% | 57.06% |
| Research & Development | 732.70K | 343.80K | 286.85K | 84.67K | 67.58K | 104.21K | 203.04K | 328.03K | 149.65K | 44.27K | 416.16K | 973.61K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.77M | 2.18M | 2.22M | 589.25K | 1.27M | 2.37M | 2.30M | 3.83M | 2.45M | 1.96M | 3.40M | 5.54M | 2.22M | 2.89M | 1.70M | 2.37M | 933.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.50K | 111.66K | 284.14K | 0.00 | 1.30K | 9.91K | 18.31K | 58.88K | 29.07K | 6.63K | 39.35K | 2.39K |
| SG&A | 1.77M | 2.18M | 2.22M | 589.25K | 1.27M | 2.39M | 2.42M | 4.11M | 2.45M | 1.97M | 3.41M | 5.56M | 2.28M | 2.92M | 1.70M | 2.41M | 936.33K |
| Other Expenses | 0.00 | 0.00 | 2.50M | 3.00K | 0.00 | -17.58K | -575.01K | 2.95K | 5.67K | 11.99K | 208.63K | 483.20K | 609.99K | 945.73K | 1.04M | 3.65M | 1.73M |
| Operating Expenses | 2.79M | 2.53M | 2.50M | 673.91K | 1.33M | 2.47M | 2.62M | 4.44M | 2.60M | 1.98M | 3.61M | 6.05M | 2.89M | 3.87M | 2.74M | 6.05M | 2.66M |
| Cost & Expenses | 2.81M | 2.55M | 2.52M | 679.52K | 1.34M | 2.47M | 2.62M | 4.44M | 2.60M | 1.98M | 3.72M | 6.12M | 2.96M | 3.94M | 2.87M | 6.21M | 2.72M |
| Interest Income | 49.58K | 0.00 | 25.38K | 287.47K | 261.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 599.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 25.38K | 287.47K | 261.37K | 5.65M | 3.90M | 6.26M | 2.66M | 2.46M | 1.60M | 1.10M | 408.47K | 860.25K | 839.63K | 219.45K | 238.98K |
| Depreciation & Amortization | 0.00 | 2.52M | 2.50M | 672.52K | 1.33M | 1.47K | 1.47K | 2.95K | 5.67K | 11.99K | 208.63K | 483.20K | 546.39K | 545.19K | 562.67K | 1.53M | 1.16M |
| EBITDA | -2.79M | 0.00 | -2.50M | -669.52K | -18.74K | -2.49M | -2.51M | -3.59M | 8.90M | -15.64M | -1.66M | -7.00M | -1.79M | -2.65M | -2.59M | -4.41M | -1.47M |
| EBITDA Ratio | -14,323.83% | -6,898.13% | -16,805.25% | -9,564.59% | -13,999.78% | 0.00% | -64,515.07% | -54,680.85% | -10,668.40% | -8,059.69% | -2,397.52% | -2,172.66% | -512.06% | -945.64% | -432.09% | -1,643.33% | -1,101.27% |
| Operating Income | -2.79M | -2.52M | -2.50M | -672.52K | -1.33M | -2.49M | -2.62M | -4.44M | -2.58M | -1.96M | -3.58M | -5.87M | -2.56M | -3.73M | -2.55M | -5.94M | -2.59M |
| Operating Income Ratio | -14,323.83% | -6,898.13% | -16,805.25% | -9,607.44% | -13,999.78% | 0.00% | -64,551.41% | -54,717.19% | -10,691.93% | -8,109.43% | -2,545.90% | -2,367.52% | -650.88% | -1,033.06% | -795.86% | -2,214.16% | -1,991.78% |
| Total Other Income/Expenses | -101.61K | 47.59K | -25.97K | -284.47K | -280.12K | -5.21M | -3.80M | -5.42M | 8.27M | -16.15M | 108.81K | -2.72M | -187.75K | -329.69K | -1.44M | -374.91K | -278.98K |
| Income Before Tax | -2.89M | -2.47M | -2.53M | -956.99K | -1.61M | -7.70M | -6.42M | -9.85M | 6.23M | -18.11M | -3.47M | -8.59M | -2.75M | -4.06M | -3.99M | -6.16M | -2.87M |
| Income Before Tax Ratio | -14,844.89% | -6,767.75% | -16,979.69% | -13,671.31% | -16,948.39% | 0.00% | -158,330.71% | -121,545.33% | 25,853.19% | -75,114.92% | -2,468.52% | -3,462.65% | -698.58% | -1,124.48% | -1,246.08% | -2,295.97% | -2,206.29% |
| Income Tax Expense | 0.00 | -47.59K | 25.38K | 287.47K | 261.37K | 5.21M | 3.90M | 6.26M | 2.66M | 2.46M | 1.60M | 1.10M | 408.47K | 479.69K | 1.44M | 0.00 | 238.98K |
| Net Income | -2.89M | -2.42M | -2.55M | -1.24M | -1.87M | -7.70M | -6.42M | -9.85M | 6.23M | -18.11M | -3.47M | -8.59M | -2.75M | -4.06M | -3.99M | -6.16M | -2.87M |
| Net Income Ratio | -14,844.89% | -6,637.37% | -17,150.14% | -17,778.04% | -19,699.69% | 0.00% | -158,330.71% | -121,545.33% | 25,853.19% | -75,114.92% | -2,468.52% | -3,462.65% | -698.58% | -1,124.48% | -1,246.08% | -2,295.97% | -2,206.29% |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.14 | -1.06 | -3.67 | 2.72 | -45.38 | -27.58 | -90.77 | -31.72 | -57.75 | -66.30 | -141.80 | -79.86 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.14 | -1.06 | -3.67 | 2.72 | -45.38 | -27.58 | -90.77 | -31.72 | -57.75 | -66.30 | -141.80 | -79.86 |
| Weighted Avg Shares Out | 368.81M | 351.43M | 325.85M | 222.80M | 175.20M | 55.50M | 6.05M | 2.69M | 2.31M | 399.09K | 125.86K | 94.59K | 86.69K | 70.22K | 60.21K | 43.43K | 35.93K |
| Weighted Avg Shares Out (Dil) | 368.81M | 351.43M | 325.85M | 222.80M | 175.20M | 55.50M | 6.05M | 2.69M | 2.31M | 399.09K | 125.86K | 94.59K | 86.69K | 70.22K | 60.21K | 43.43K | 35.93K |
Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics
Richland WA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it certified three additional clinics to offer Isopet® Precision Radionuclide Therapy (PRT).
Why Cyclo, Vivos Therapeutics And More Are Moving Today
Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a U.S.-based biotechnology firm engaged in the marketing and...
Source: https://incomestatements.info
Category: Stock Reports